Allterum Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
Allterum is focused on developing 4A10, a highly selective, best-in-class mAb targeting IL-7Ra subunit (CD127) expressing cells. As you may be aware this JAK-STAT pathway, which happens to be downstream from the IL-7R, is clinically validated in both oncology and inflammation. Our mAb, 4A10, initially developed by Dr. Scot Durum at the NIH, has repeatedly shown strong activity, a favorable safety profile in NHPs, and a high affinity (15x vs. the native IL-7 ligand) to CD127.
We are on track to file our first IND in 2Q25, initially for R/R B/T-ALL, a CD127-driven malignancy. This indication represents a significant unmet need with the potential for accelerated approval based on single-arm ph2 data, and we currently face no competition in this area. This unlocks a substantial value inflection point within the next 24mo. We also plan on expanding the development of 4A10 into other heme-onc indications (AML, CML, NHL), solid tumors expressing CD127, and autoimmune disorders (e.g., UC, RA).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}